Sun Set To Get Taro Deal Over The Line, 17 Years After First Trying
Indian Firm Owns 78.5% Of Taro; Paying $43 Per Share For Remainder
More than a decade after a renewed bid to take control of Taro failed, Sun Pharma is set to take full control of the Israeli-based derma specialist, which has seen material growth and much controversy in the US under Sun’s ownership.
